Floatz logo

Zactima

Refractory Pediatric AML

Samsung Medical CenterPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Refractory Pediatric AML cohort.

Asset / SponsorPhaseRating
Ifosfamide
Samsung Medical Center
Phase 2CCC
gw786034
Samsung Medical Center
Phase 2CCC
Imatinib
Samsung Medical Center
Phase 2CCC
TRASTUZUMAB
Samsung Medical Center
Phase 2CCC
Axitinib
Samsung Medical Center
Phase 2CCC

View all 10 →

Same molecule, other indications

Zactima is also rated in:

gliosarcomaDormant
B
Indicative ·
63 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →